Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.

ABSTRACT:

Objective

Recycling tenofovir and lamivudine/emtricitabine (XTC) with dolutegravir would provide a more tolerable, affordable, and scalable second-line regimen than dolutegravir with an optimized nucleoside reverse transcriptase inhibitor (NRTI) backbone. We evaluated efficacy of tenofovir/lamivudine/dolutegravir (TLD) in patients failing first-line tenofovir/XTC/efavirenz or nevirapine.

Design

Single arm, prospective, interventional study.

Setting

Two primary care clinics in Khayelitsha, South Africa.

Participants

Sixty adult patients with two viral loads greater than 1000 copies/ml.

Intervention

Participants were switched to TLD with additional dolutegravir (50 mg) for 2 weeks to overcome efavirenz induction.

Primary outcome

Proportion achieving

SUBMITTER: Keene CM 

PROVIDER: S-EPMC7612028 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature